Medical Device Giant Masimo Announces New CEO Amid Strategic Transformation
Masimo
Developer, Manufacturer, and Seller of Medical Monitoring Instruments
Medtronic
Medical Device Manufacturer
Source: Medical Device Business Review
Author: Yu Bai
Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.
After four months of turmoil, since Kiani, the iron-handed leader, was ousted from the board of directors and removed from the position of CEO,Leader in Non-Invasive Monitoring TechnologyMasimo(Masimo)Finally, the new CEO has been officially announced., a highly anticipated leadership change is gradually coming to an end.
Who is the new head coach? What will the future hold for this leading medical device company, which once confronted Apple and caused the suspension of Apple Watch sales in the U.S.?
Yesterday (January 21, 2025), Masimo announced the appointment of Katie Szyman as the new Chief Executive Officer, effective February 12, 2025.
Newly Appointed Masimo CEO Katie Szyman
The new CEO has an impressive resume.
Szyman currently serves asBDGlobal President of Advanced Patient Monitoring.
She previously ledEdwardThe intensive care business (BD acquired this business in September for $4.2 billion) hasMore than a decade，Accelerated revenue growth by shifting to AI-driven solutions and led the launch of the first FDA-approved AI technology in the patient monitoring field.
Before joining Edwards, Szyman also worked atMedtronicWorkedMore than 20 years, and has held increasingly important positions, includingLeadership roles in corporate strategy, business development, and finance, as well as Global President of the Endovascular and Diabetes divisions.
Regarding the appointment of Ms. Szyman, all parties expressed optimism.
Masimo stated in its announcement: "The Board is confident that Ms. Szyman, with her proven track record of successfully launching new patient monitoring products to accelerate revenue growth,Her extensive experience in leading and retaining top industry talent, along with her broad and strong network within the industry, makes her undoubtedly the ideal candidate for this position.”
BTIG analysts Marie Thibault, Sam Eiber, and Alexandra Pang also stated that Szyman's appointment is "Highly Matched”。
The analyst wrote: "We believe that as Masimo transitions into a pure healthcare company, the search for a former CEOKianiThe successor's work has finally come to a successful conclusion. We are delighted to see this news because we believeSzymanThe woman is very suitable for this position."
Michelle Brennan, the former interim CEO, will become the Chair of the Board of Masimo, and Quentin Koffey, the Lead Independent Director, has been appointed as Vice Chair. These changes will also take effect on February 12.
Masimo Corporation, established in 1989, is globally recognizedLeader in Non-Invasive Monitoring Technology, committed to the development and production of various leading monitoring technologies and equipment in the medical industry, including meters, sensors, pulse oximeters, patient monitors, and automated devices, etc.
With solid technology and promising wealth creation prospects,Apple、Samsung、GoogleTech giants alike have been eyeing it covetously, evenPhilipsIt was also fined $466 million (approximately RMB 3.3 billion) in a 2014 patent dispute with Masimo Corporation.
However, before Szyman's appointment, this leading company experienced an extremely turbulent year.Founder and former CEO Joe Kiani was forced to resign and removed from the position of chairman of the board. This was followed by a major reshuffle of the team, and by the end of 2024, the company announced layoffs at its headquarters.
The new CEO taking over from Kiani must inevitably regroup amidst the past "storm and stress."
"Before 'testing new wine with new tea,' we might as well take a brief look back at the departure of former CEO Kiani and the rise and fall of Masimo."
The story begins with the hot topic of Kiani taking on Apple.
In January 2020, Masimo Corporation filed a lawsuit against Apple for the first time, accusing it of stealing the company's trade secrets by establishing a working relationship with Masimo and poaching key employees, including Masimo's former Chief Medical Officer and Cercacor's former Chief Technology Officer.
In September 2020, amidst this legal backdrop, the Apple Watch Series 6 was officially released, with the blood oxygen monitoring feature introduced as a key selling point. This allowed users to measure blood oxygen saturation levels directly from their wrist using the "Blood Oxygen" app on the Apple Watch Series 6.
After a three-year patent battle, in January 2023, the U.S. International Trade Commission (ITC) announced that Apple had lost the case, and Masimo won the first round of the U.S. trade case regarding the ban on importing Apple Watches.
Kiani admitted that Masimo spent approximately US$100 million (equivalent to RMB 700 million) solely on legal fees for this dispute. In this patent showdown,While defending intellectual property rights, Kiani also saw the huge gold-mining potential in the consumer electronics business of its rivals. Thus, as the scales of victory tipped in favor of Masimo, Kiani's ambition continued to grow.
In the evolution of the technological wave, many tech giants have extended their reach into the field of vital signs monitoring, which has inspired Kiani to explore cross-disciplinary ideas.
However, Kiani, who was eager to expand his territory, overlooked the potential risks of cross-border mergers and acquisitions.
In February 2022, Kiani set his sights on consumer health and decided to invest $1.025 billion (approximately7.413 billionRMB) to acquire audio manufacturer Sound United, the amount is large enough to make it into the top ten M&A list in the global medical device field in 2022.
However, the reasoning behind this massive acquisition appears somewhat rash and highly subjective.
Kiani stated that he is a loyal fan of Sound United and is committed to "adding Sound United's superior technology, well-established consumer channels, and renowned brands to Masimo's extensive portfolio of hospital and home medical technology solutions."
"Masimo's expertise in advanced signal processing, biosensing, and photonics technology, combined with Sound United's audio and home automation technology, will bring natural yet non-intuitive solutions to people in homes and hospitals worldwide."
Sound United is a leading consumer technology company with several well-known premium audio and home entertainment brands, including Bowers & Wilkins, Denon, Polk Audio, Marantz, Definitive Technology, Classé, and Boston Acoustics.
Indeed, Sound United has notable achievements in the audio field, but comparing Sound United with Masimo's core business of "oxygen saturation monitoring," it is not difficult to see that the connection between the two is not strong.
This landmine has undoubtedly exploded in subsequent performance results.
In July 2024, Masimo released its financial statements, and the performance of the consumer sector was not optimistic.
This business is expected to generate $152 million in revenue this quarter, a decrease of $22 million compared to $174 million in revenue in the second quarter of fiscal year 2023.A decrease of up to 13%。
Revenue from Masimo's former Sound United business plummeted.
On a quarterly basis, the company's revenue was $208 million in 2022, dropped to $174 million in 2023, and the latest earnings for this quarter were $152 million.
The signals of declining revenue and weak acquisitions are also intuitively reflected in the stock price.The company's stock price has fallen 60% since 2021, and Masimo's glory days are gradually fading.
The magma of discontent beneath the company's crust has finally found a vent, with investors directing their anger at Kiani, the decision-maker behind the acquisition of Sound United to expand the consumer business.
03
Following Kiani's example, the primary task for the new leader, Szyman, upon taking office is to "correct the course" and set a new direction.
Current Chairman Brennan stated: "The next CEO will prioritize our product lines, focus on big opportunities, and establish a clear strategy to bring our next-generation patient monitoring platform to market."
It can be seen that divesting consumer health and focusing on medical monitoring business has become the main theme for Masimo's future.
So, is the prospect of this new strategy all bright? What challenges will the newly started Masimo face?
When it comes to the intensive care track, it is impossible not to mention the high figure in 202442Hundred MillionUSD (approximately30.4 billionRMB) giant mergers and acquisitions,This is also the second-largest M&A transaction in the medical device field in 2024 after Johnson & Johnson's acquisition of Shockwave.
At that time, Edwards Life Sciences had been operating its critical care products division for many years.Business (The leader is Szyman)Sold to BD Medical, focusing intently on heart valves.
Although the intensive care business is a high-growth sector for Edwards, compared to the company's core business—structural heart disease treatment,Its synergy is relatively low.By selling, Edwards Life Sciences can focus more on its areas of expertise, streamline and optimize its operations, thereby improving overall operational efficiency and profitability.
On the other hand, BD Medical, whose business focus is on critical care, can further strengthen its competitiveness through this.
Masimo's spin-off of its consumer health business to focus on the monitoring track follows the same logic.
The direction of the intensive care track is becoming increasingly clear—it is accelerating towards a future where resources are more concentrated.
Technological Innovation, AI Empowerment
Many experts in the field of critical care have proposed that healthcare is the industry with the highest compatibility with AI.
With the continuous development of technologies such as artificial intelligence, the Internet of Things (IoT), and cloud computing, the trend toward intelligentization and digitalization of critical care equipment is becoming increasingly evident.
The recently released Mindray's critical care large model is a typical example. On December 14, 2024, the People's Data Conference · AI Empowering Smart Healthcare, hosted by People's Daily Online, was held in Beijing. At the conference, Mindray Medical unveiled for the first time the "Qiyuan Large Model" jointly developed with Tencent. This is alsoThe World's FirstLarge Model for Clinical Application in Critical Care.
As artificial intelligence technology continues to advance, its application in the field of critical care is gradually deepening, not only optimizing efficiency and processes but also significantly enhancing monitoring capabilities. From macro-management to micro-details, it demonstrates remarkable potential across the board.
In addition, it was mentioned earlier that Szyman has also had successful cases of combining AI with intensive care in the past, and in the future...Masimo's direction also has considerable room for imagination.
Conclusion
After a series of production line reorganizations and personnel changes, Masimo, as a leader in the industry, is undergoing an unprecedented trial. However, it is precisely these challenges and upheavals that are fostering new opportunities and possibilities for the development of the field.. Looking forward to a new chapter for Masimo!
The content of this article is for reference only and does not constitute investment advice. Readers are expected to effectively distinguish.If any platform reprints this article, it must take responsibility for the content of the article. Medical Device Business Review is not responsible for the impact of secondary dissemination caused by reprints.
*Advertisement
▼More Book Recommendations▼
In order not to miss any content, everyone remembers toMedical Device Business ReviewSet as Star? Oh,
Looking forward to meeting you at the first moment every time
